Breakthrough in Huntington’s Disease Treatment
Scientists may have made significant progress in the fight against Huntington’s disease, a serious brain condition that has had no effective treatments until now. Researchers from University College London (UCL) recently revealed encouraging findings from a global clinical trial concerning a new gene therapy named AMT-130.
Developed by the Dutch biotechnology company uniQure, AMT-130 is the first therapy tested directly on Huntington’s disease patients. This condition, a rare and heritable brain disorder, gradually damages nerve cells and typically begins between the ages of 30 and 50 due to a mutation in the HTT gene. This mutation produces a harmful protein called huntingtin, leading to various debilitating symptoms.
Patients with Huntington’s often face issues with movement, memory, and emotions. Common challenges include involuntary movements, stiffness, walking difficulties, and problems with speaking and swallowing. The disease can also cause memory loss and concentration issues, ultimately leading to significant disability and, in many cases, death within 20 years of symptom onset.
AMT-130 is administered as a one-time gene therapy injected into the brain, introducing new, functional DNA through a neurosurgical procedure. This treatment is designed to reduce the production of the harmful huntingtin protein.
In a three-year trial at UCL involving 29 patients, those who received a higher dosage of AMT-130 showed a dramatic 75% decrease in disease progression compared to those who received standard treatments. The evaluation of disease progression used the Unified Huntington’s Disease Rating Scale, which tracks motor, cognitive, and everyday functional abilities.
Moreover, levels of neurofilament light protein (NfL), a marker found in the spinal fluid of Huntington’s patients that indicates neuronal damage, were monitored. Participants receiving AMT-130 experienced less of this protein, which would typically rise between 20% and 30% over a similar time frame. Overall, the drug was well-tolerated, with a manageable safety profile.
Professor Sarah Tabrizi, the lead scientific advisor at UCL, stated, “These groundbreaking data provide some of the clearest evidence we have of a treatment that could modify Huntington’s disease, which is urgently needed.”
AMT-130 holds promise for preserving the daily lives of patients, potentially allowing them to remain active in their work and slow down the disease’s progression. Professor Ed Wild from UCL noted this could be a transformative step in the treatment of Huntington’s disease, expressing hope that AMT-130 will be the first licensed therapy to slow down the condition.
Dr. Earnest Lee Murray, a neurologist based in Tennessee, acknowledged the challenges in treating Huntington’s disease, particularly the difficulty in identifying effective treatment targets. He emphasized the importance of this potential treatment, stating, “The fact that we potentially have a medication that alters the disease course is certainly promising.”
While the trial is a positive step, Dr. Lee pointed out some limitations, including the small number of participants. Future studies will be necessary to confirm the effectiveness of AMT-130 and monitor any possible side effects. The trial results will be presented next month at the HD Clinical Research Congress in Nashville.
Looking ahead, uniQure plans to submit an application to the FDA for accelerated approval of AMT-130 early next year. Professor Wild emphasized the need to ensure the treatment is accessible to everyone who requires it and to continue the search for additional effective therapies.
